Figure (Andexxa 01)
Andexxa Injection, Powder, Lyophilized, For Solution
Product Images NDC 0310-3200
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Andexxa (NDC 0310-3200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure A (Andexxa 02)
Figure B (Andexxa 03)
Figure Ii (Andexxa 04)
Figure A 14 (Andexxa 05)
This appears to be a chart or table with headings for different treatments or interventions (Placebo bolus and ANDEXKA) and the number of individuals in each group (8 and 23, respectively). The chart also includes time points (in hours) after an initial bolus dose of each treatment, followed by "End of Bolus" and "End of Infusion" labels. However, the actual data in the table (represented by the string of numbers) is not available or readable.*
Figure B 14 (Andexxa 06)
Carton 200mg mL (Andexxa 07)
The text describes Andexxa, a powder for solution that contains coagulation factor Xa (recombinant), inactivated-zhzo. It comes in four single-dose vials and must be stored refrigerated. After reconstitution, each vial contains 200 mg coagulation factor Xa (recombinant), inactivated-zhzo, tris base, trs hydrochloride, L-arginine hydrochloride, sucrose, mannitol, and polysorbate 80. The dosage and administration information can be found in the enclosed package insert. It is manufactured by AstraZeneca AB in Sweden and distributed by AstraZeneca Pharmaceuticals LP in Wilmington, Delaware.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
